Company / Accounts Receivable
IOVANCE BIOTHERAPEUTICS, INC. Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$82.4M
FY2025
5-year range
$151.0K / $82.4M
FY2023-FY2025
Trend
+18.9%
vs FY2024
Sector context
#62 of 115
Health Care
What the data says
At $82M, IOVANCE BIOTHERAPEUTICS, INC.'s accounts receivable ranks #62 of 115 in the Health Care sector. Improved from $151,000 to $82M over the past 2 years.
Based on SEC 10-K filings.
$82M in FY2025.
Improved from $151,000 to $82M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#62 of 115 in Health CareTop 54% of 115This company $82.4M Sector average $1.1B
▼
-92.6% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 18.9% year-over-year.
- Ranks #62 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.4M | +18.9% |
| FY2024 | $69.3M | +45820.5% |
| FY2023 | $151.0K | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026